Could a new HIV treatment reduce the need for lifelong medication?
Researchers found that a new treatment approach may help control HIV without the need for lifelong medication. The ACTG, a global clinical trials network, presented findings at AIDS 2026 that highlight two key areas: efforts to find a cure for HIV and the impact of aging on individuals living with the virus. The studies suggest that a biologic treatment called N-803, used alone or with broadly neutralizing antibodies (bNAbs), can significantly reduce the HIV reservoir in the body, which is crucial for managing the virus effectively.
For people living with HIV, these findings could mean a future where they might not have to rely on antiretroviral therapy (ART) indefinitely. In the study, participants who received N-803 experienced a 37% reduction in the HIV reservoir after five doses, and some have remained off ART for at least 24 weeks. This could lead to improved quality of life and a better understanding of how to control HIV without daily medication, especially for those who may struggle with the side effects or the burden of constant treatment.
The research is still in the early stages, with the findings based on a small human trial and preliminary data. While the results are promising, more extensive studies are needed to confirm the effectiveness of N-803 and determine who might benefit most from this treatment. Additionally, another study presented at the conference explored how chronic inflammation from HIV can accelerate aging and cognitive decline, suggesting that protecting certain sugars in the body may help mitigate these effects.
As researchers continue to explore these avenues, people living with HIV should stay informed about new treatments and discuss them with their healthcare providers to optimize their health and well-being.